Document Detail

Statin treatment for patients with heart failure.
MedLine Citation:
PMID:  20234351     Owner:  NLM     Status:  MEDLINE    
Statins may be beneficial for the prevention and treatment of heart failure, as indicated by large observational studies, small prospective studies, and post hoc analyses of cardiovascular databases. Two large, prospective, controlled trials have, however, shown that rosuvastatin has neutral effects on the survival of patients with chronic heart failure. The benefits of statin treatment seem to mostly result from their ability to halt disease progression in heart failure, particularly in patients with coronary artery disease. Based on these results, statin treatment might only be useful for the prevention of heart failure, and possibly in patients with new-onset heart failure. This Review highlights data from observational data analyses as well as from the large prospective trials investigating the safety and efficacy of statins in patients with heart failure. The results from these studies and their implications for the timing of initiating statin therapy in this patient population are also discussed.
W H Wilson Tang; Gary S Francis
Publication Detail:
Type:  Journal Article; Review     Date:  2010-03-16
Journal Detail:
Title:  Nature reviews. Cardiology     Volume:  7     ISSN:  1759-5010     ISO Abbreviation:  Nat Rev Cardiol     Publication Date:  2010 May 
Date Detail:
Created Date:  2010-04-26     Completed Date:  2010-07-27     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101500075     Medline TA:  Nat Rev Cardiol     Country:  England    
Other Details:
Languages:  eng     Pagination:  249-55     Citation Subset:  IM    
Department of Cardiovascular Medicine, Cleveland Clinic Heart and Vascular Institute, 9500 Euclid Avenue, Cleveland, OH 44195, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Cohort Studies
Dose-Response Relationship, Drug
Drug Administration Schedule
Follow-Up Studies
Heart Failure / diagnosis,  drug therapy*,  mortality*
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
Randomized Controlled Trials as Topic
Risk Assessment
Severity of Illness Index
Survival Analysis
Treatment Outcome
Reg. No./Substance:
0/Hydroxymethylglutaryl-CoA Reductase Inhibitors

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The Safety and Efficacy of Celecoxib in Children With Familial Adenomatous Polyposis.
Next Document:  mTOR signaling and drug development in cancer.